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S U M M A R Y
Objectives: Most are aware of pneumococcal infection as a complication of splenectomy and the
increased risk of severe invasive pneumococcal disease (IPD) in asplenic patients. However little is
known of the current status of this entity in a population with an active pneumococcal conjugate vaccine
program for children.
Methods: All IPD cases reported from 2000 to 2014 in Northern Alberta, Canada were collected
prospectively. Socio-demographic variables, clinical characteristics, and IPD-related outcomes were
compared between patients with and without a spleen using the Student t-test, Chi-square test, or
Fisher’s exact test, as appropriate.
Results: Thirty-seven of 2435 patients with IPD (1.5%) were asplenic. Asplenic patients were signiﬁcantly
more likely to require mechanical ventilation or admission to the intensive care unit and had more
complications (e.g., acute kidney injury). However, in-hospital mortality rates were similar in those with
and without a spleen (19% vs. 16%, p = 0.58). Pneumococcal serotype 22B was 33-fold higher in asplenic
patients compared to those with a spleen.
Conclusions: In patients with IPD, those who are asplenic have a more severe infection than those with a
spleen; however, the mortality rate is not signiﬁcantly different. The reason for the predominance of
serotype 22B requires further investigation and if replicated may warrant attention to current
vaccination strategies.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Splenic macrophages remove poorly opsonized bacteria
(those that are encapsulated, like Streptococcus pneumoniae)
from the blood stream very efﬁciently.1 In addition, the spleen is
the major site of synthesis of immunoglobulin M and opsonins
such as tuftsin and properidin.1 It is no surprise then that
overwhelming pneumococcal sepsis can occur in splenectomized
patients.2,3 While encapsulated microorganisms other than S.
pneumoniae can cause bacteremia in splenectomized persons, in
a study of 52 asplenic patients with sepsis compared with
52 septic patients with their spleens, S. pneumoniae was more* Corresponding author. Tel.: +1-780-492-6333; fax: +1-780-492-7455.
E-mail address: deurich@ualberta.ca (D.T. Eurich).
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1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).frequently detected amongst the asplenic group (42% vs. 12%),
whilst the rate of Gram-negative sepsis was similar in the two
groups.4
There is very little current information on the extent and nature
of the problem of pneumococcal sepsis in the asplenic patient, and
splenectomy itself is not uncommon. In Alberta, Canada, approxi-
mately 150 splenectomies are performed each year (Li Huang,
Alberta Health Services, personal communication). Conjugated
pneumococcal vaccines have been used in Alberta since the early
2000s. The 7-valent pneumococcal conjugate vaccine (PCV7) was
introduced for children in Alberta in 2002 and the 13-valent
pneumococcal vaccine (PCV13) in 2010. There is a standardized
clinical policy that all patients receive pneumococcal, meningo-
coccal, and Haemophilus inﬂuenzae vaccines either prior to
splenectomy, if possible, or prior to hospital discharge post
splenectomy.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Comparison of IPD patients with no spleen and IPD patients with a spleen
No spleen Spleen p-Value
Number 37 (1.5%) 2398 (98.5%) -
Age, years, mean (SD) 58.6 (13.7) 54.2 (17.9) 0.13
Male 18 (49%) 1362 (57%) 0.32
Aboriginal 0 (0%) 312 (13%) 0.011a
Living at home 36 (97%) 1924 (81%) 0.026a
Homeless 0 (0%) 184 (8%)
Fully functional 28 (76%) 1727 (72%) 0.62
Current smoker 8 (22%) 1096 (46%) 0.003
Cancer past 5 years 12 (32%) 295 (12%) <0.001
Hepatitis C 1 (3%) 306 (13%) 0.078
Chronic renal failure 3 (8%) 124 (5%) 0.44
HIV infection 0 117 (5%) 0.25a
Systemic lupus erythematosus 1 (3%) 16 (1%) 0.23
COPD 3 (8%) 438 (18%) 0.13
Alcoholism 4 (11%) 616 (26%) 0.039
Illicit drug use 1 (3%) 481 (20%) 0.006
IPD, invasive pneumococcal disease; SD, standard deviation; COPD, chronic
obstructive pulmonary disease.
a Corrected for zero cell.
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manifestations and outcomes of invasive pneumococcal disease
(IPD). This study formed part of a prospective 15-year study of IPD
in Northern Alberta, Canada.
2. Methods
2.1. Deﬁnitions
Cases of IPD were deﬁned as per the Alberta Health Public
Health Notiﬁable Disease Management Guidelines (http://www.
health.alberta.ca/documents/ Guidelines-Pneumococcal-Disease-
Invasive-IPD-2011).5 Pneumococcal isolates from cases of invasive
disease were collected from normally sterile sites deﬁned as blood,
cerebrospinal ﬂuid, pleural ﬂuid, peritoneal ﬂuid, pericardial ﬂuid,
bone, joint or specimens taken during surgery. As per the
aforementioned guidelines, all IPD isolates were submitted to
the Provincial Laboratory for Public Health (PLPH) located in
Edmonton, Alberta for capsular serotyping.
2.2. Clinical data collection
Cases of IPD were identiﬁed through an isolate database housed
at the PLPH. An IPD case list was generated. Research nurses
retrospectively collected clinical data for each case using this list.
Socio-demographic, clinical, functional, and laboratory data were
collected using a standardized case report form (CRF). From
2000 to 2014, data were collected on all patients in Northern
Alberta with IPD (approximate population 2 060 039). The
research nurses received training on data collection prior to the
start of the study. In addition to the CRF, standard operating
procedures documents, deﬁnitions, drug classiﬁcation, and under-
lying illness categorization were part of their working documents.
With respect to underlying illnesses, if the attending physician
recorded such an illness it was accepted as such for the purpose of
the study. Acute kidney failure was speciﬁcally deﬁned as an
absolute increase in serum creatinine of 100 mmol/l over the
baseline creatinine, or any requirement for dialysis. This study
received approval from the institutional research review commit-
tees of all Northern Alberta health regions, as well as the University
of Alberta ethics review board.
2.3. Identiﬁcation and serotyping of S. pneumoniae isolates
S. pneumoniae isolates were received at the PLPH from acute
diagnostic laboratories in Alberta, as per the requirements of the
provincial notiﬁable disease guidelines. S. pneumoniae isolates
were conﬁrmed as S. pneumoniae based on characteristic
morphology and optochin susceptibility prior to serotyping.6 All
pneumococcal isolates that exhibited a positive Quellung reaction
using commercial type-speciﬁc antisera obtained from Statens
Serum Institute, Copenhagen, Denmark were assigned a serotype
designation.7
2.4. Exposures and outcomes
The independent variable of interest was asplenia; it was
speciﬁcally asked whether the patient had undergone a splenec-
tomy, and patients were categorized into those with or without a
spleen based on these data. Patients who had a spleen were
classiﬁed into the spleen group regardless of spleen function. The
primary outcomes of interest were the occurrence of major in-
hospital complications deﬁned as the presence of cellulitis,
osteomyelitis, septic arthritis, meningitis, admission to the
intensive care unit (ICU), need for mechanical ventilation, acute
kidney injury, and all-cause in-hospital mortality. In addition,serotyping of all isolates was performed and the results were
stratiﬁed and described according to the presence or absence of a
spleen.
2.5. Statistical analysis
The analyses were largely descriptive in nature. Socio-
demographic variables, clinical characteristics, and IPD-related
outcomes were compared between patients with and without a
spleen using the Student t-test, Chi-square test, or Fisher’s exact
test, as appropriate. All analyses were performed with Stata SE,
version 12.1 (Stata, College Station, TX, USA).
3. Results
3.1. General description
Thirty-seven (1.5%) of the 2435 patients identiﬁed with IPD in
the study were asplenic. Table 1 provides a comparison of IPD
patients who were asplenic and those who were not. Patients who
were identiﬁed as asplenic were more likely to be living at home
(p = 0.026) and to have had a solid tumor cancer within the past
5 years (p < 0.001). They were, however, less likely to be aboriginal
(p = 0.011), have alcoholism (p = 0.039), or use illicit drugs
(p = 0.006), and were less likely to have chronic obstructive
pulmonary disease (p = 0.13).
3.2. Outcomes according to the presence or absence of a spleen
Table 2 shows the pre-speciﬁed outcomes stratiﬁed according
to the presence or absence of a spleen. Those without a spleen had
a more severe infection as measured by markers of supportive
treatment intensity, such as the need for mechanical ventilation
(p = 0.008) and ICU admission (p = 0.001). They were also more
likely to have complications of pneumococcal bacteremia such as
meningitis (p < 0.001), as well as complications of severe sepsis
such as acute kidney injury (p < 0.001) (Table 2). Although the all-
cause in-hospital mortality rate of 19% amongst those with no
spleen was higher than that of 16% for those who had a spleen, this
3% absolute difference in mortality was not statistically signiﬁcant
(p = 0.58). Even in terms of those with the most severe IPD, 19
(51.4%) of the asplenic patients were admitted to the ICU and six
(31.6%) died compared to 664 (27.7%) of the patients with a spleen
of whom 192 (28.9%) died.
Table 2
Outcomes of IPD amongst patients with and without a spleen
No spleen (37 cases) Spleen (2398 cases) p-Value
Intensive care admission 19 (51.4%) 664 (27.7%) 0.001
Mechanical ventilation 15 (40.5%) 532 (22.2%) 0.008
Meningitis 8 (21.6%) 112 (4.7%) <0.001
Cellulitis 1 (2.7%) 64 (2.7%) 1
Osteomyelitis 0 7 (0.3%) 1
Septic arthritis 1 (2.7%) 39 (1.6%) 0.46
Acute kidney injury 7 (18.9%) 92 (3.8%) <0.001
Liver failure 2 (5.4%) 60 (2.5%) 0.24
Died in hospital 7 (18.9%) 374 (15.6%) 0.58
IPD, invasive pneumococcal disease.
Table 3
The two most frequent pneumococcal serotypes causing IPD amongst 37 patients
with no spleen and 2398 with a spleen
Serotype No spleen Spleen p-Value
23B 10 (27.0%) 20 (0.8%) <0.0001
22F 7 (18.9%) 169 (7.0%) 0.006
Total 17 (45.9%) 189 (7.8%)
IPD, invasive pneumococcal disease.
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Table 3 shows the two most common infecting pneumococcal
serotypes according to the presence or absence of a spleen. Two
serotypes, 23B and 22F combined, accounted for 45.9% of the
infections in the asplenic group, but only 7.8% of the infections in
the patients with a spleen. Serotype 23B with 10 isolates (27.0%)
was 33 times more frequent in the asplenic group than in those
with a spleen. The remaining serotypes in the asplenic group were
15C, 19A, 23A, 33A (two isolates of each) and 4, 9, 10A, 11A, 12F, 13,
15A, 20, 23F, 34, 35B (one isolate of each) and one non-type able
serotype. Two of the serotypes causing infection in the asplenic
patients, serotypes 4 and 23F, are in PCV7 (5.4%); these two plus
two isolates of 19A are in PCV13 (10.8%) and an additional
11 isolates – 10A, 11A, 12F, 20 (one each), and 22F (seven) – are in
PPV23 (40.5%). Twenty-one of the remaining serotypes (23B
(10 isolates), 15C, 23A, 33A (two isolates each), and 9, 13, 15A, 23,
34, 35B (one isolate each)) are not in any of the currently available
vaccines, and one isolate was non-type able.
4. Discussion
This study revealed several new ﬁndings that are important
with respect to the management of patients with IPD in the
absence of a spleen. Currently, the mortality rate for those with IPD
and asplenia is not signiﬁcantly different from that of patients who
have a spleen. This study, extended over 15 years, included a total
of 2435 patients with IPD of whom 37 (1.5%) lacked a spleen. This
number of cases is larger than various previously published case
series or single-center experiences, and a review of the existing
literature indicates that this study provides comprehensive
current data that ﬁll an important gap in studies on the morbidity
and mortality from IPD in asplenic patients from the late 1990s
through to the present2–4,8–11.
For instance, Rubin and Schaffner recently reviewed the care of
the asplenic patient and found that amongst children with sickle
cell disease and presumably functional asplenia and IPD, the
mortality rate declined from 18% in the mid 1980s to 2–10% in
studies of cases between 1994 and 2007. This article does not give
current data on the mortality rate in asplenic adult patients with
IPD, but indicates that between 1966 and 1996 it was 46%.11
In the current study, the pneumococcal infection in the asplenic
group was more severe as judged by markers of supportivetreatment intensity, which included ICU admission, mechanical
ventilation, complications such as meningitis, and acute kidney
injury; however, in both absolute and relative terms, the mortality
rate was similar to that in those with a spleen. This still represents
an improvement in comparison to earlier studies.2,3 Whether this
is due to general improvements in the care of very sick patients,
partial protection afforded by pneumococcal vaccination, in-
creased ‘herd’ immunity, or other factors is unclear. The asplenic
group was not healthier than those with a spleen and had some of
the risk factors for IPD-related mortality, as was found in a
previous study.12
With the widespread application of pneumococcal vaccines
there has been a change in serotype distribution causing IPD. In
Germany, there has been an increase in serotypes 15A and 23B in
the post pneumococcal conjugate vaccine era.13 If this were the
case in Alberta, one would not expect a differential increase in
infecting serotypes in the splenectomy population unless other
factors are operative. Rodrigo and Lim cited a study of adults with
IPD in which older adults and individuals with a greater level of
comorbid illness were affected by serotypes 3, 6A, 6B, 8, 19F, and
23 and this resulted in more severe illness and led to higher
mortality in comparison with IPD due to serotypes 1 and 7F.14
In 2002, shortly after the onset of this study, PCV7 was
incorporated into the childhood immunization program in Alberta,
and in 2010 it was replaced by PCV13.15 PPV23 has been used in
Alberta since the late 1980s. There is now ample evidence of the
effectiveness of PCV7 and PCV13. In the USA, PCV7 was 96%
effective against vaccine serotypes in healthy children and 81%
effective in those with co-existing diseases.16 This beneﬁcial effect
has had a secondary beneﬁcial effect in adults, where use of PCV13
in children has resulted in an overall decrease in IPD amongst
adults of 12–32%, with a 58–72% decline for IPD due to PCV13
serotypes.17 This beneﬁcial effect is offset somewhat by the
increase in IPD by non-pneumococcal conjugate vaccine serotypes,
i.e., replacement serotypes.18
Patients who have had their spleen removed have been advised
to be vaccinated against pneumococci since the availability of
PPV23; more recently the recommendations have been updated to
indicate that these individuals should receive both PPV23 and
PCV13.19,20 Fifty-nine percent of the infecting serotypes amongst
the asplenic patients in the present study were not in any of the
currently available vaccines. The paucity of vaccine serotypes
causing infection may represent vaccine efﬁcacy. The predomi-
nance of serotype 23B, which accounted for 27% of the isolates
amongst the asplenic patients, is even more noteworthy when one
considers that it was 33 times more common than in the patients
with a spleen. The reasons for this remain to be determined.
A crude estimate of asplenic patients at risk and the IPD rate
amongst these patients can be calculated using some ‘back of the
envelope’ calculations and might be informative. There were
75 splenectomies in Northern Alberta per year yielding
825 patients over the duration of the study. It is reasonable to
assume a ‘steady state’, since splenectomies have been performed
for some time and it is estimated that the number of asplenic
persons at risk of IPD each year is likely around 3000. With
2.46 cases of IPD amongst the splenectomy group per year in
Northern Alberta, the rate of IPD is 82/100 000 adults. In the early
conjugate vaccine era, the rate of IPD amongst adults >60 years
(this group has the highest IPD rate amongst adults) in the USA was
49/100 000 per year.17 Thus the rate of IPD amongst splenecto-
mized patients is close to double (at least 1.67 times) the rate
amongst adults with the highest rate in the early conjugate vaccine
era. Clearly, splenectomy remains a major risk factor for IPD.
This study has several strengths: (1) the large sample size, (2)
the wealth of clinical data, and (3) the availability of pneumococcal
serotyping data, all of which are critical for providing an accurate
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limitations. First, the study was not designed to determine why
patients who have undergone a splenectomy get IPD or whether
the IPD occurred early or late following splenectomy. Furthermore,
it could not examine the issue of ‘functional’ asplenia, which may
be more common than realized. Second, the indications for
splenectomy in these patients are not known. Third, by design, it
was not possible to capture pneumococcal disease not associated
with bacteremia, nor could investigations of the infections due to
other encapsulated organisms that patients with asplenia are
prone to be performed. Fourth, there was no detailed information
regarding vaccination status. As asplenic patients are routinely
advised to receive pneumococcal vaccination, one may have
expected to see a reduction in serotypes included in the vaccines
with a possible shift to non-vaccine-related serotypes. Although an
increase in 23B was seen – a serotype not included in the vaccines –
asplenic patients also had a much higher rate of 22F, which is
included in the current vaccine. Thus, how vaccinations could have
affected the serology results is difﬁcult to surmise. Fifth, this study
may not have had sufﬁcient power to ﬁnd statistical differences in
mortality between splenic and asplenic patients; however, even in
absolute terms, the mortality rates were similar. Moreover,
mortality information once the patient was discharged from
hospital was not available, and nor was information regarding
changes in functional status or post-discharge morbidities
associated with illness.
It is concluded that asplenic patients constitute a minority of
patients with IPD and whilst their infection is more severe, their
all-cause in-hospital mortality rate is similar to that of patients
with a spleen. A predominance of pneumococcal serotypes 23B and
22F in this population was noted. These ﬁndings suggest that the
rate of IPD in this population is still too high and that targeted
programs to reduce this rate are necessary. It is clear that
pneumococcal vaccination recommendations in those who under-
go splenectomy should be addressed carefully, and if these ﬁndings
are replicated, existing vaccines should be reformulated to include
additional serotypes in this population.
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